Chica Mori

TL;DR: It is demonstrated that chronic nasal administration of Aβ peptide can induce an immune response to Aβ that decreases cerebral Aβ deposition, suggesting a novel mucosal immunological approach for the treatment and prevention of AD.

TL;DR: It is concluded that Aβ42 accumulates intracellulary prior to extracellular Aβ deposition in Down syndrome, and that subsequent maturation of extrace cellular Aβ deposits elicits inflammatory responses and precedes NFTs.

TL;DR: The data suggest that in AD and DS, the classical complement cascade is activated after compaction of Abeta42 deposits and, in some instances, can progress to the local neuronal expression of the MAC as a response to Abeta plaque maturation.

TL;DR: It is concluded that following active immunization, anti-Aβ antibodies sequester serum Aβ and may increase central nervous system to serum A β clearance in mouse models of Alzheimer’s disease.

TL;DR: In an effort to reduce the inflammation associated with Aβ deposition via mucosal tolerance, the effects of nasal or oral administration of Aβ1–40 peptide and a control protein, myelin basic protein, were tested by treating 52 PD-APP transgenic mice on a weekly basis for seven months.